CONTINUE TO SITE

Or wait...

News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs

Sign in Register

Sign out My account

Search

Bio Developments

Upstream Processing

Downstream Processing

Markets & Regulations

Biopharma Culture

Promotional Features

Site Archive

April 2024
March 2024
All News

Multimedia

Videos
Podcasts
Photo Galleries

Antibody-Drug Conjugates

Emerging Markets

Cell & Gene Therapies

Site Archive

April 2024
March 2024
All News

Multimedia

Videos
Podcasts
Photo Galleries

Analytical (technologies & services)
Bio-Outsourcing
Bioreactors
Cell lines
Disposable Manufacturing Tech
Facilities
Fill-Finish & Packaging
Separation & Purification

Type of resources

Library
Technical Papers
Product Brochures
Videos & Audio
Supplier Webinars
Suppliers

Shows & Conferences

Editorial Webinars

Events

All Events

Outsourcing-Pharma.com

Register

Home
Headlines
Hot Topics
Resources
Events
Resources
Related Site
- Outsourcing-Pharma.com
Sign up to our newsletters
Sign out
My account

Register

Account & Access
Sign in
Register
Sign out
My account

BIO9

By Zachary Brennan

26-Jun-2014 - Last updated on 27-Jun-2014 at 07:21 GMT

Prev
1
5
6
7
8
9
10
Next

Copyright - Unless otherwise stated all contents of this web site are © 2024 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Related news

Genzyme offers inside look at Massachusetts plant under consent decree
Kalon building $91m vaccine manufacturing facility in Texas for GSK partnership

Follow us

Webinars

On-demand webinars

Cell and Gene Therapy Manufacturing Webinar
Innovation in Drug Delivery Webinar

Headlines

SynOx Therapeutics secures $75m to fund tenosynovial giant cell tumor trial
Hospitalized incident cases of MRSA to reach 791,000 in 2033
SK pharmteco to manufacture Ferring Pharmaceuticals’ gene therapy for bladder cancer
Pharma goes urban: The rise of city manufacturing facilities
What is ‘chemo mouth’ and could a brand new treatment offer relief?
US to see surge in new obesity drug launches in next five years
Eli Lilly’s double impact: Mounjaro and Donanemab to ‘outshine’ market rivals

BioPharma-Reporter

Advertise with us
Why Register?
Apply to reuse our content
Press Releases – Guidelines
About us
Contact the Editor
Report a technical problem

Resources

Whitelist our newsletters
Editorial Calendar
RSS Feed
Podcast
FAQ